In one, a North Carolina lab allegedly billed for unnecessary urine drug tests, and in the other a Californian women submitted fraudulent claims for respiratory pathogen testing.

The firm reported that its full-year 2024 revenues were up slightly as a rise in the diagnostics business was mostly offset by a decline in life sciences business.

The firm reported that its full-year 2024 revenues were up slightly as a rise in the diagnostics business was mostly offset by a decline in life sciences business.

AlterDiag will take full responsibility for the industrialization, regulatory restrictions, and commercialization of the tests.

The small Baltimore-based lab is preparing for the possibility of additional appeals as years of litigation wind down.

Quest said that while it will continue to look at acquisition opportunities, it plans to focus on integrating and driving productivity of recently purchased assets.

While Roche saw a 1 percent decline in full-year 2024 diagnostics sales year over year, the base business within the division rose 8 percent. Overall, Roche reported ...

NEW YORK – Medicare administrative contractors Novitas and First Coast Service Options have postponed the implementation dates of two final local coverage determinations that rescinded coverage for ...

NEW YORK – Danaher executives said Wednesday that the firm expects the effects from the volume-based procurement program in China and anticipated lower respiratory testing volumes will have an impact ...

Roche plans to release the system in the US to run tests including vitamin D and steroid assays under CLIA before it possibly receives US Food and Drug Administration clearance.

The test, which is intended for assessing cardiovascular risk, is the first lipoprotein (a), or Lp(a) test measured in nanomoles per liter to receive FDA clearance.